Ibogaine targets opioid addiction with a 24-72 hour session and real cardiac risk; ayahuasca targets depression and trauma in a 4-8 hour ceremony with a serious MAOI drug-interaction risk.
Ibogaine vs ayahuasca is a comparison people make when they are already exploring plant-medicine work and want to understand how these two very different substances stack up. Both are Schedule I in the US, both usually mean travel to a retreat or clinic abroad, and both carry serious, non-negotiable safety screening requirements — but the similarities mostly end there. This guide compares mechanism, evidence, safety, legal status, and cost side by side.
Ibogaine is the substance to consider if opioid addiction is the primary problem — no other psychedelic has as strong a single-session signal for easing withdrawal and cravings, though it demands rigorous cardiac screening and is one of the most physically demanding psychedelic experiences that exists. Ayahuasca is the better fit for someone working through depression, grief, or trauma who wants a traditional, ceremonial container for that work, provided they can complete a full medication washout beforehand. Neither is legal for general use in the US, and both typically mean traveling to a retreat or clinic abroad.
| Factor | Ibogaine | Ayahuasca |
|---|---|---|
| Primary use case | Opioid and alcohol use disorder; trauma in veteran populations | Depression, grief, and trauma processing in a ceremonial context |
| Legal status (US) | Schedule I. No FDA approval. No religious or state exemption. | Schedule I (contains DMT). Legal only via four DEA-recognized religious exemptions. |
| Session duration | 24–72 hours, with days of recovery afterward. | 4–8 hours, usually one ceremony per night across a multi-night retreat. |
| How it works | Complex multi-receptor action: NMDA antagonist, kappa-opioid agonist, sigma-1, and 5-HT2A. Active metabolite noribogaine persists for days. | B. caapi vine (harmaline/harmine — an MAOI) combined with P. viridis (DMT, a 5-HT2A agonist). The MAOI stops gut breakdown of DMT, which is why the brew works orally. |
| Key safety concern | QT-interval prolongation; risk of fatal ventricular arrhythmia. Pre-session EKG and cardiac workup are mandatory. | MAOI drug interactions — SSRIs, SNRIs, lithium, and stimulants can trigger serotonin syndrome. Full medication washout required beforehand. |
| Physical experience | Intense, dream-like, often described as a "life review"; minimal purging. | Purging (vomiting, sometimes diarrhea) is common and considered part of the ceremony by many traditions. |
| Evidence stage | Phase 1/2 data; FDA Breakthrough Therapy designation for opioid use disorder; no Phase 3 RCT yet. | Phase 2 randomized, placebo-controlled trial data for depression; no Phase 3 trial or FDA designation. |
| Where to access it legally | International clinics (Mexico, Costa Rica, Portugal) or an FDA-authorized (IND) trial in the US. | International retreats (Peru, Brazil, Costa Rica, the Netherlands) or one of the four US religious exemptions. |
| Typical cost | $3,000–$8,000+ for a full clinic program; some luxury facilities run $12,000+. | $1,500–$5,000 for a multi-night retreat, not including travel and accommodation. |
| Insurance coverage | None. Out of pocket. | None. Out of pocket. |
Ibogaine, from the Tabernanthe iboga shrub native to Central Africa, is pharmacologically unusual: it acts on multiple receptor systems at once, including NMDA (like ketamine), kappa-opioid and sigma-1 receptors, and serotonin 5-HT2A receptors (like classic psychedelics). Its active metabolite, noribogaine, lingers in the body for days, which may explain much of its lasting anti-craving effect. Read our full ibogaine guide for the complete mechanism and safety picture.
Ayahuasca is a two-plant brew: the B. caapi vine supplies MAOI compounds (harmaline, harmine, tetrahydroharmine) that block the gut enzyme which would otherwise destroy orally-taken DMT, and P. viridis supplies that DMT. At the receptor level, DMT is a 5-HT2A agonist — the same core mechanism as psilocybin and LSD — which places ayahuasca in the "classic psychedelic" family in a way ibogaine is not. Our ayahuasca guide covers the full pharmacology and the MAOI interaction risk in depth.
The practical difference: ibogaine's multi-receptor, opioid-adjacent action is thought to explain its addiction-interruption effect in a way ayahuasca's more classically-psychedelic mechanism does not replicate.
Ibogaine produces some of the most striking single-session results in addiction medicine. A 2018 observational study (Mash et al.) found that a single ibogaine session substantially reduced opioid and cocaine use in participants at 30 days post-treatment.1 In 2024, Stanford's MISTIC protocol gave magnesium-ibogaine to 30 Special Operations veterans and reported large drops in PTSD, anxiety, and depression scores.2 In 2025, Texas approved a $50 million consortium (IMPACT) to run FDA-track ibogaine trials for addiction, PTSD, and TBI.3 Still, most ibogaine evidence comes from small, open-label studies rather than large controlled trials.
Ayahuasca's best evidence is a 2019 randomized, placebo-controlled trial in Brazil (Palhano-Fontes et al., Psychological Medicine), which found rapid antidepressant effects after a single session compared with an inactive herbal tea placebo.4 The trial was small (n=29) and conducted under controlled clinical conditions — not the same setting as an international retreat. Open-label observational data from the same research group and others consistently show antidepressant and trauma-related benefit, but no large Phase 3 trial or FDA designation exists for ayahuasca.
Both ibogaine and ayahuasca are Schedule I controlled substances federally, with no FDA-approved use — but the narrow legal paths around each differ. Ayahuasca has four DEA-recognized religious exemptions (UDV, Santo Daime, and two smaller organizations) that allow those specific groups sacramental use; joining one is not a practical access route for most people, so international retreats in Peru, Brazil, Costa Rica, and the Netherlands are the typical path. Ibogaine has no equivalent US exemption at all — the only legal US access is an FDA-authorized (IND) clinical trial, such as the new Texas IMPACT consortium, and most people instead travel to a clinic in Mexico, Costa Rica, or Portugal.
See our guide to what psychedelics are legal in the US for the full state-by-state picture, or the which psychedelic quiz if you are not yet sure which substance fits your situation.
Ibogaine can dangerously prolong the heart's QT interval, which raises the risk of torsades de pointes, a potentially fatal arrhythmia. A published review linked at least 19 deaths to ibogaine, many during opioid detox.5 Reputable clinics require a 12-lead EKG, a full cardiac workup, and continuous monitoring — this is a prerequisite, not an optional precaution.
Ayahuasca's harmala alkaloids inhibit MAO enzymes, so any medication that raises serotonin — SSRIs, SNRIs, most antidepressants, some pain medications — can trigger serotonin syndrome in combination.6 Washout periods typically run two to four weeks (five weeks for fluoxetine). Lithium is a hard contraindication. Beyond medications, purging (vomiting, sometimes diarrhea) is common and, in many traditions, considered part of the healing process.
Neither risk is "worse" than the other — they are unrelated failure modes, and a person considering both substances (at different points, never together) needs a full, independent screening for each: cardiac for ibogaine, medication review for ayahuasca.
Integration therapy afterward matters for both. Find a therapist trained in psychedelic integration through our therapist finder, or compare vetted retreat and clinic options with our retreat finder.
Lean toward ibogaine if opioid addiction is your primary problem, other treatments have not worked, and you can reach a clinic or trial with full cardiac screening and monitoring. Its single-session effect on withdrawal is unlike anything else in psychedelic medicine — but never outside a medically-supervised, heart-monitored setting.
Lean toward ayahuasca if you are working through depression, grief, or trauma and want a traditional ceremonial container for that work, and you can complete a full medication washout beforehand. Its evidence is real but earlier-stage, and the purging and ceremonial structure are part of what many people find meaningful about it.
Some people, as several podcast guests describe, move through both at different points in a longer healing path — but that path only works safely with a fresh, independent screening before each substance, never a shared one.
Ibogaine has the far stronger addiction signal, especially for opioid use disorder — people often report that one session sharply eases withdrawal and cravings. Ayahuasca's strongest evidence is for depression and trauma, not addiction, though some retreat centers report anecdotal benefit for problem drinking and other substance use. If addiction, and opioids specifically, is the primary goal, ibogaine is the substance with real clinical signal behind it.
Some people do move between plant medicines — microdosing, then an ayahuasca ceremony, then ibogaine — as part of a longer personal healing path, and podcast guests describe exactly this progression. But the two should never be taken close together or without a full medical and medication review between them: ibogaine's cardiac risk and ayahuasca's MAOI drug interactions are both serious and unrelated, so each session needs its own independent screening, not a shared one.
They carry different, both-serious risks rather than one being simply 'more dangerous.' Ibogaine can prolong the heart's QT interval and trigger fatal arrhythmias — a published review linked at least 19 deaths to ibogaine, mostly from missed cardiac screening. Ayahuasca's harmala alkaloids are MAO inhibitors that can cause life-threatening serotonin syndrome when combined with SSRIs, SNRIs, lithium, or stimulants. Both require a full medical and medication review — cardiac for ibogaine, a medication washout for ayahuasca — before any session.
Ibogaine is far longer. A full ibogaine experience runs 24 to 72 hours, with days of recovery afterward. An ayahuasca ceremony lasts 4 to 8 hours, typically through a single night, and a retreat usually involves several ceremonies over 5 to 10 days.
Neither is legal for general use — both contain Schedule I controlled substances. Ayahuasca has a narrow legal path: four DEA-recognized religious exemptions (UDV, Santo Daime, and two smaller churches) can use it sacramentally, though joining one isn't a practical option for most people. Ibogaine has no US religious or state exemption at all — the only legal US access is through an FDA-authorized (IND) clinical trial, such as the Texas IMPACT consortium. Most people accessing either substance travel to a retreat or clinic abroad.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.